Test Price
2,800 AED✅ Home Collection Available
ELANE Gene Sequencing for Severe Congenital Neutropenia Type 1 (NGS) in the UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل جين ELANE لقلة العدلات الخلقية الشديدة من النوع الأول في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary (الملخص التنفيذي)
- Diagnostic Precision: 99.9% analytical sensitivity and specificity via ISO 9001:2015 accredited next‑generation sequencing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital‑grade cold‑chain home collection by certified phlebotomists (8 AM–11 PM), ensuring sample integrity.
- Clinical Guidance: Complimentary telephonic post‑test interpretation with a DHA‑licensed specialist to discuss results and next steps.
- Insurance & Payments: Direct billing verification through WhatsApp at +971 54 548 8731; all major UAE insurers accepted.
يقدم اختبار تسلسل جين ELANE دقة تشخيصية بنسبة 99.9% عبر معالجة مخبرية معتمدة وفق معيار ISO 9001:2015. تشمل الخدمة السحب المنزلي المبرد وفق أعلى معايير النقل، ودعم سريري لاحق عبر الهاتف من أطباء مرخصين من هيئة الصحة بدبي. تحقق من تغطية تأمينك مباشرة عبر واتساب. هذا الفحص ضروري لتأكيد قلة العدلات الخلقية الشديدة من النوع الأول والتخطيط للعلاج.
Test Overview
The ELANE gene NGS test identifies pathogenic variants causing severe congenital neutropenia type 1 (SCN1), a rare inherited bone marrow failure disorder characterised by persistent neutropenia and recurrent infections. تحليل جين ELANE باستخدام تقنية التسلسل الجيني المتقدم يكشف الطفرات المسببة لقلة العدلات الخلقية الشديدة، مما يدعم التشخيص الدقيق والمراقبة المستمرة. This test uses whole‑blood, extracted DNA, or FTA cards with a turnaround time of 3 to 4 weeks.
| Feature | Our NGS Test (ELANE Full Sequencing) | Closest Alternative (Targeted Sanger) |
|---|---|---|
| Methodology | Next‑Generation Sequencing with high‑depth coverage of all exons, splice sites, and known regulatory regions | Sanger sequencing of a limited number of preselected exons |
| Detection Rate | >99% of pathogenic variants, including novel mutations | Detects only known mutations in targeted regions; may miss rare variants |
| Reporting Speed | 3–4 Weeks | 2–3 Weeks (faster but less comprehensive) |
| Clinical Utility | Enables genotype‑phenotype correlation, G‑CSF therapy planning, and family screening | Suitable for already‑known familial variants only |
Physician Insight & Safety Protocol
“As a DHA‑licensed Hematologist, I recommend the ELANE NGS gene test to families with suspected severe congenital neutropenia because early molecular confirmation guides life‑saving treatment with G‑CSF and antibiotic prophylaxis. Remember, a genetic result is only one piece of the clinical puzzle – it must be interpreted alongside the full blood count, bone marrow findings, and the child’s infection history. لا يمكن الاستغناء عن التقييم السريري الشامل.”
— Dr. Prabhakar Reddy, DHA License 61713011
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active febrile illness (temperature >38.0°C), recent whole‑blood transfusion within 2 weeks, or ongoing systemic infection requiring intravenous antibiotics. In these cases, postpone specimen collection until the patient is clinically stable.
- Emergency Red Flags – Seek Immediate Medical Attention: High‑grade fever >38.5°C with chills, painful mouth ulcers, skin abscesses, or any signs of sepsis (rapid breathing, confusion, cold/clammy skin). These may indicate a life‑threatening neutropenic crisis.
- Always inform the laboratory if the patient is on granulocyte colony‑stimulating factor (G‑CSF); recent administration may affect blood counts but does not interfere with genetic testing.
UAE Regulatory & E‑E‑A‑T Compliance
- Federal Decree-Law No. 41 of 2024 (Art. 87): This genetic test is performed exclusively in a DHA‑licensed facility (License No. 9834453), ensuring strict adherence to human genomic data protection and prohibition of genetic discrimination.
- CDS Law 2026 (Minors): For paediatric patients, informed consent must be obtained from a legal guardian, and results are disclosed only in the presence of the referring paediatrician or genetic counsellor.
- UAE PDPL (Personal Data Privacy Law): All patient genomic data are encrypted, stored on UAE‑based servers, and never shared without explicit consent. Your privacy is protected at every step.
- ISO 9001:2015 Certified: Laboratory processes conform to ISO 9001:2015 (Certificate: INT/EGQ/2509DA/3139), guaranteeing quality management from sample accessioning to report delivery.
Patient FAQ & Clinical Guidance
Q: What does the ELANE gene test diagnose, and how does it help my child?
Direct Answer: This test confirms severe congenital neutropenia type 1 caused by ELANE mutations, enabling doctors to start G-CSF therapy early to prevent life-threatening infections.
For paediatric patients, an early molecular diagnosis transforms management: it clarifies the risk of recurrent bacterial infections and justifies lifelong surveillance by a paediatric hematologist. يؤكد هذا التحليل التشخيص الجيني لقلة العدلات الخلقية الشديدة من النوع الأول، مما يساعد الأطباء على البدء الفوري بعلاج عامل تحفيز الخلايا الحبيبية للوقاية من العدوى الخطيرة.
Q: How is the test performed and what is the sample requirement?
Direct Answer: A certified phlebotomist collects a small blood sample (3–5 mL in an EDTA tube) or a finger-prick onto an FTA card, all during a home visit.
We also accept previously extracted DNA if it meets quality standards. A mandatory pre‑ genetic counselling session will be scheduled to draw a detailed family pedigree and explain the implications. يتم سحب عينة دم بسيطة أو بقعة دم على بطاقة FTA خلال زيارة منزلية؛ يسبق ذلك جلسة إرشاد وراثي إلزامية لرسم شجرة العائلة.
Q: What support do I receive after the results are available?
Direct Answer: You will receive a comprehensive ISO‑accredited report, followed by a telephonic consultation with a DHA‑licensed specialist to explain the findings and coordinate care.
We also facilitate direct referrals to paediatric hematologists in Dubai and Abu Dhabi for patients with confirmed SCN1. Insurance reimbursement assistance is provided via WhatsApp at +971 54 548 8731. بعد صدور التقرير المعتمد، تحصل على استشارة هاتفية مع أخصائي مرخص من هيئة الصحة لتفسير النتائج وتنسيق الرعاية اللازمة.
Primary Specialists & Clinical Intent
Top Relevant Specialists: Hematologist, Pediatrician, Clinical Geneticist.
Clinical Intent: Confirm pathogenic ELANE variants in patients with persistent neutropenia and suspicion of SCN1; guide treatment with G‑CSF, prophylaxis, and hematopoietic stem cell transplantation considerations; offer accurate recurrence risk assessment and carrier testing to family members.
Collaborating Specialties: Neonatology, Oncology, Sports Science (for differential diagnosis of benign ethnic neutropenia), and Genetic Counseling.
2026 Method & Medical Coding
Methodology: Next‑Generation Sequencing (NGS) with bioinformatic analysis using Illumina NovaSeq platform, targeting all exons, splice junctions, and 5′/3′ UTRs of the ELANE gene. Validated with orthogonal confirmation of pathogenic/likely pathogenic variants.
2026 ICD‑10‑CM Codes: D70.0 (Congenital agranulocytosis), Z15.89 (Genetic susceptibility to other disease), D70.8 (Other neutropenia).
LOINC Code: 93685-6 – ELANE gene full mutation analysis in Blood or Tissue by Sequencing
Schedule your home collection or verify insurance:
WhatsApp +971 54 548 8731Available 8 AM – 11 PM, 7 days a week. DHA License: 9834453
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians